Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population

Abstract

Objective: Prior evaluations of ulcerative colitis (UC)-related costs are dated or encompassed limited follow-up. This study assessed the incremental direct and indirect work loss-related costs of privatelyinsured patients with UC in the United States, overall and in specific subgroups. Methods: In this retrospective matched cohort study, the OptumHealth Care Solutions, Inc (formerly Optum Health Reporting and Insights employer) database (01 January 1999-31 March 2017) was used to identify adult patients with !2 claims for UC, who were matched 1:5 to patients with no claims for inflammatory bowel disease (IBD). UC subgroups were identified based on indicators during the observation period (i.e. use of biologics, opioids, or corticosteroids; UC-related surgery; moderate-to-severe disease; UC-related comorbidities). Healthcare resource utilization (HRU), work loss days, and direct and work loss-related costs were compared between matched cohorts. Descriptive analyses of direct and work loss-related costs were conducted within each UC subgroup. Results: Compared to the non-IBD cohort (n ¼ 46,765), the UC cohort (n ¼ 9353) incurred higher HRU, including 128% more inpatients visits, resulting in $11,029 higher direct costs per patient per year

Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents

“…The remaining 4837 studies were screened on title and abstract and 4730 excluded. After full‐text screening, 64 of the remaining 107 studies were included in the systematic review 32‐95 . No missed studies were found in the reference lists of the other systematic reviews.…”

“…Longitudinal data to assess changes in total and component costs for incident cases were not available for different time periods. Most studies reported annual healthcare costs for incident cases in the time period 2008-2012, 42,47,70,71,73,76,92,93,95 and other incidencebased studies reported healthcare costs in the first ten years after diagnosis. 67,77 Mean annual IBD-attributable costs of incident CD and UC cases in the first year after diagnosis were assessed in seven studies (Table 3).…”

“…67,77 Mean annual IBD-attributable costs of incident CD and UC cases in the first year after diagnosis were assessed in seven studies (Table 3). 42,70,73,76,92,93,95 Three of these studies were conducted Only pediatric (n = 5)…”

“…Not all studies included the same cost components, and valuation methods differed considerably. For example, North American studies often reported insurance claims as costs, possibly leading 36,37,45,48,52,56,57,62,84,95 As most studies only reported costs and not resource use, it was not possible to determine if a difference in resource use explained cost differences or whether this was due to differing prices per resource. We aimed to reduce heterogeneity by stratifying studies based on disease and geographical area.…”

Evaluation of economic burden with biologic treatments in Crohn’s disease patients: A mirror image study using an insurance database in Japan

“…Patients with inflammatory bowel disease (IBD) experience lower HRQoL; higher absenteeism, presenteeism, and work and activity impairment; higher HRU; and higher direct and indirect costs compared with the general population [17,[44][45][46][47]. However, comparing IBD with other diseases may reveal the true burden of IBD on society.…”